Vidcast: https://youtu.be/g7fZjuKlmYc

The Danish biotechnology company AdaptVac is developing a CoVid vaccine based on technology different than the mRNA tech used for the Moderna and Pfizer vaxes, the adenovirus vector J&J and AstraZeneca vaxes, and the protein-based Novavax offering. The AdaptVac vaccine, labeled ABNCoV2 uses a viral capsid-like particle derived from an E. coli bacteriophage to present spike protein and other CoVid antigens to the human immune system.

A phase 1 first human study of the vaccine tested 45 subjects with two doses of the ABNCoV2 vaccine. The data revealed healthy anti-CoVid antibody and cellular immune responses with minimal side effects.

This viral capsid vaccine permits a rapid modification of the viral antigens it carries permitting manufacture of a vaccine against the latest CoVid variants. Hence the name of the company: AdaptVac.

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22)00337-8/fulltext

#CoVid #vaccine #phagecapid #ABNCoV2 #AdaptVac